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Abstract
Background: Patients with prostate cancer may present with metastatic or recurrent disease despite initial curative
treatment. The propensity of metastatic prostate cancer to spread to the bone has limited repeated sampling of
tumor deposits. Hence, considerably less is understood about this lethal metastatic disease, as it is not commonly
studied. Here we explored whole-genome sequencing of plasma DNA to scan the tumor genomes of these
patients non-invasively.
Methods: We wanted to make whole-genome analysis from plasma DNA amenable to clinical routine applications
and developed an approach based on a benchtop high-throughput platform, that is, Illuminas MiSeq instrument.
We performed whole-genome sequencing from plasma at a shallow sequencing depth to establish a genome-
wide copy number profile of the tumor at low costs within 2 days. In parallel, we sequenced a panel of 55 high-
interest genes and 38 introns with frequent fusion breakpoints such as the TMPRSS2-ERG fusion with high
coverage. After intensive testing of our approach with samples from 25 individuals without cancer we analyzed 13
plasma samples derived from five patients with castration resistant (CRPC) and four patients with castration
sensitive prostate cancer (CSPC).
Results: The genome-wide profiling in the plasma of our patients revealed multiple copy number aberrations
including those previously reported in prostate tumors, such as losses in 8p and gains in 8q. High-level copy number
gains in the AR locus were observed in patients with CRPC but not with CSPC disease. We identified the TMPRSS2-
ERG rearrangement associated 3-Mbp deletion on chromosome 21 and found corresponding fusion plasma
fragments in these cases. In an index case multiregional sequencing of the primary tumor identified different copy
number changes in each sector, suggesting multifocal disease. Our plasma analyses of this index case, performed 13
years after resection of the primary tumor, revealed novel chromosomal rearrangements, which were stable in serial
plasma analyses over a 9-month period, which is consistent with the presence of one metastatic clone.
Conclusions: The genomic landscape of prostate cancer can be established by non-invasive means from plasma
DNA. Our approach provides specific genomic signatures within 2 days which may therefore serve as ‘liquid
biopsy’.
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Background
Prostate cancer is the most common malignancy in
men. In Europe each year an estimated number of 2.6
million new cases is diagnosed [1]. The wide application
of PSA testing has resulted in a shift towards diagnosis
at an early stage so that many patients do not need
treatment or are cured by radical surgery [2]. However,
patients still present with metastatic or recurrent disease
despite initial curative treatment [3]. In these cases pros-
tate-cancer progression can be inhibited by androgen-
deprivation therapy (ADT) for up to several years. How-
ever, disease progression is invariably observed with
tumor cells resuming proliferation despite continued
treatment (termed castration-resistant prostate cancer or
CRPC) [4]. CRPC is a strikingly heterogeneous disease
and the overall survival can be extremely variable [5].
Scarcity of predictive and prognostic markers underlines
the growing need for a better understanding of the
molecular makeup of these lethal tumors.
However, acquiring tumor tissue from patients with
metastatic prostate cancer often represents a challenge.
Due to the propensity of metastatic prostate cancer to
spread to bone biopsies can be technically challenging and
limit repeated sampling of tumor deposits. As a conse-
quence, considerably less is understood about the later
acquired genetic alterations that emerge in the context of
the selection pressure of an androgen-deprived milieu [6].
Consistent and frequent findings from recent genomic
profiling studies in clinical metastatic prostate tumors
include the TMPRSS2-ERG fusion in approximately
50%, 8p loss in approximately 30% to 50%, 8q gain in
approximately 20% to 40% of cases, and the androgen
receptor (AR) amplification in approximately 33% of
CRPC cases [7-10]. Several whole-exome or whole-gen-
ome sequencing studies consistently reported low over-
all mutation rates even in heavily treated CRPCs [9-14].
The difficulties in acquiring tumor tissue can partly be
addressed by elaborate procedures such as rapid autopsy
programs to obtain high-quality metastatic tissue for
analysis [15]. However, this material can naturally only
be used for research purposes, but not for biomarker
detection for individualized treatment decisions. This
makes blood-based assays crucially important to indivi-
dualize management of prostate cancer [16]. Profiling of
blood offers several practical advantages, including the
minimally invasive nature of sample acquisition, relative
ease of standardization of sampling protocols, and the
ability to obtain repeated samples over time. For exam-
ple, the presence of circulating tumor cells (CTCs) in
peripheral blood is a prognostic biomarker and a mea-
sure of therapeutic response in patients with prostate
cancer [17-20]. Novel microfluidic devices enhance CTC
capture [21-23] and allow to establish a non-invasive
measure of intratumoral AR signaling before and after
hormonal therapy [24]. Furthermore, prospective studies
have demonstrated that mRNA expression signatures
from whole blood can be used to stratify patients with
CRPC into high- and low-risk groups [25,26].
Another option represents the analysis of plasma DNA
[27]. One approach is the identification of known altera-
tions previously found in the resected tumors from the
same patients in plasma DNA for monitoring purposes
[28,29]. Furthermore, recurrent mutations can be identi-
fied in plasma DNA in a subset of patients with cancer
[30-32]. Given that chromosomal copy number changes
occur frequently in human cancer, we developed an
approach allowing the mapping of tumor-specific copy
number changes from plasma DNA employing array-
CGH [33]. At the same time, massively parallel sequen-
cing of plasma DNA from the maternal circulation is
emerging to a clinical tool for the routine detection of
fetal aneuploidy [34-36]. Using essentially the same
approach, that is, next-generation sequencing from
plasma, the detection of chromosomal alterations in the
circulation of three patients with hepatocellular carci-
noma and one patient with both breast and ovarian can-
cer [37] and from 10 patients with colorectal and breast
cancer [38] was reported.
However, the costs of the aforementioned plasma
sequencing studies necessary for detection of rearrange-
ments were prohibitive for routine clinical implementa-
tion [37,38]. In addition, these approaches are very
time-consuming. Previously it had been shown that
whole-genome sequencing with a shallow sequencing
depth of about 0.1x is sufficient for a robust and reliable
analysis of copy number changes from single cells [39].
Hence, we developed a different whole-genome plasma
sequencing approach employing a benchtop high-
throughput sequencing instrument, that is, the Illumina
MiSeq, which is based on the existing Solexa sequen-
cing-by-synthesis chemistry, but has dramatically
reduced run times compared to the Illumina HiSeq [40].
Using this instrument we performed whole-genome
sequencing from plasma DNA and measured copy
number from sequence read depth. We refer to this
approach as plasma-Seq. Furthermore, we enriched 1.3
Mbp consisting of exonic sequences of 55 high-interest
cancer genes and 38 introns of genes, where fusion
breakpoints have been described and subjected the DNA
to next-generation sequencing at high coverage
(approximately 50x). Here we present the implementa-
tion of our approach with 25 plasma samples from indi-
viduals without cancer and results obtained with whole
genome sequencing of 13 plasma DNA samples derived
from nine patients (five CRPC, four CSPC) with prostate
cancer.
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Methods
Patient eligibility criteria
This study was conducted among men with prostate can-
cer (Clinical data in Additional file 1, Table S1) who met
the following criteria: histologically-proven, based on a
biopsy, metastasized prostate cancer. We distinguished
between CRPC and CSPC based on the guidelines on
prostate cancer from the European Association of Urology
[41], that is: 1, castrate serum levels of testosterone (testos-
terone <50 ng/dL or <1.7 nmol/L); 2, three consecutive
rises of PSA, 1 week apart, resulting in two 50% increases
over the nadir, with a PSA >2 ng/mL; 3, anti-androgen
withdrawal for at least 4 weeks for flutamide and for at
least 6 weeks for bicalutamide; 4, PSA progression, despite
consecutive hormonal manipulations. Furthermore, we
focused on patients who had ≥5 CTCs per 7.5 mL [19]
and/or a biphasic plasma DNA size distribution as
described previously by us [33].
The study was approved by the ethics committee of
the Medical University of Graz (approval numbers 21-
228 ex 09/10, prostate cancer, and 23-250 ex 10/11, pre-
natal plasma DNA analyses), conducted according to the
Declaration of Helsinki, and written informed consent
was obtained from all patients and healthy blood
donors. Blood from prostate cancer patients and from
male controls without malignant disease was obtained
from the Department of Urology or the Division of
Clinical Oncology, Department of Internal Medicine, at
the Medical University of Graz. From prostate cancer
patients we obtained a buccal swab in addition. Blood
samples from pregnant females and from female con-
trols without malignant disease were collected at the
Department of Obstetrics and Gynecology, Medical Uni-
versity of Graz. The blood samples from the pregnant
females were taken prior to an invasive prenatal diag-
nostic procedure.
Plasma DNA preparation
Plasma DNA was prepared using the QIAamp DNA
Blood Mini Kit (Qiagen, Hilden, Germany) as previously
described [33]. Samples selected for sequence library
construction were analyzed by using the Bioanalyzer
instrument (Agilent Technologies, Santa Clara, CA,
USA) to observe the plasma DNA size distribution. In
this study we included samples with a biphasic plasma
DNA size distribution as previously described [33].
Enumeration of CTCs
We performed CTC enumeration using the automated
and FDA approved CellSearch assay. Blood samples (7.5
mL each) were collected into CellSave tubes (Veridex,
Raritan, NJ, USA). The Epithelial Cell Kit (Veridex) was
applied for CTC enrichment and enumeration with the
CellSearch system as described previously [42,43].
Array-CGH
Array-CGH was carried out using a genome-wide oligo-
nucleotide microarray platform (Human genome CGH
60K microarray kit, Agilent Technologies, Santa Clara,
CA, USA), following the manufacturer’s instructions
(protocol version 6.0) as described [33]. Evaluation was
done based on our previously published algorithm
[33, 44, 45].
HT29 dilution series
Sensitivity of our plasma-Seq approach was determined
using serial dilutions of DNA from HT29 cell line (50%,
20%, 15%, 10%, 5%, 1%, and 0%) in the background of nor-
mal DNA (Human Genomic DNA: Female; Promega,
Fitchburg, WI, USA). Since quantification using absorp-
tion or fluorescence absorption is often not reliable we
used quantitative PCR to determine the amount of ampli-
fiable DNA and normalized the samples to a standard
concentration using the Type-it CNV SYBR Green PCR
Kits (Qiagen, Hilden, Germany). Dilution samples were
then fragmented using the Covaris S220 System (Covaris,
Woburn, MA, USA) to a maximum of 150-250 bp and 10
ng of each dilution were used for library preparation to
simulate plasma DNA condition.
Plasma-Seq
Shotgun libraries were prepared using the TruSeq DNA
LT Sample preparation Kit (Illumina, San Diego, CA,
USA) following the manufacturer´s instructions with
three exceptions. First, due to limited amounts of plasma
DNA samples we used 5-10 ng of input DNA. Second,
we omitted the fragmentation step since the size distribu-
tion of the plasma DNA samples was analyzed on a Bioa-
nalyzer High Sensitivity Chip (Agilent Technologies,
Santa Clara, CA, USA) and all samples showed an enrich-
ment of fragments in the range of 160 to 340 bp. Third,
for selective amplification of the library fragments that
have adapter molecules on both ends we used 20-25 PCR
cycles. Four libraries were pooled equimolarily and
sequenced on an Illumina MiSeq (Illumina, San Diego,
CA, USA).
The MiSeq instrument was prepared following routine
procedures. The run was initiated for 1x150 bases plus
1x25 bases of SBS sequencing, including on-board clus-
tering and paired-end preparation, the sequencing of the
respective barcode indices and analysis. On the comple-
tion of the run, data were base called and demultiplexed
on the instrument (provided as Illumina FASTQ 1.8 files,
Phred+33 encoding). FASTQ format files in Illumina 1.8
format were considered for downstream analysis.
Calculation of segments with identical log2 ratio values
We employed a previously published algorithm [46] to
create a reference sequence. The pseudo-autosomal region
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(PAR) on the Y chromosome was masked and the mapp-
ability of each genomic position examined by creating vir-
tual 150 bp reads for each position in the PAR-masked
genome. Virtual sequences were mapped to the PAR-
masked genome and mappable reads were extracted. Fifty
thousand genomic windows were created (mean size,
56,344 bp) each having the same amount of mappable
positions.
Low-coverage whole-genome sequencing reads were
mapped to the PAR-masked genome and reads in differ-
ent windows were counted and normalized by the total
amount of reads. We further normalized read counts
according to the GC content using LOWESS-statistics. In
order to avoid position effects we normalized the sequen-
cing data with GC-normalized read counts of plasma
DNA of our healthy controls and calculated log2 ratios.
Resulting normalized ratios were segmented using circu-
lar binary segmentation (CBS) [47] and GLAD [48] by
applying the CGHweb [49] framework in R [50]. These
segments were used for calculation of the segmental z-
scores by adding GC-corrected read-count ratios (read-
counts in window divided by mean read-count) of all the
windows in a segment. Z-scores were calculated by sub-
tracting mean sum of GC-corrected read-count ratios of
individuals without cancer (10 for men and 9 for women)











Calculation of z-scores for specific regions
In order to check for the copy-number status of genes
previously implicated in prostate-cancer initiation or
progression we applied z-score statistics for each region
focusing on specific targets (mainly genes) of variable
length within the genome. At first we counted high-
quality alignments against the PAR-masked hg19 gen-










Then we subtracted the mean ratio of a group of con-
trols and divided it by the standard deviation of that
group.
zregion =
ratiosample − mean (ratiocontrols)
SD (ratiocontrols)
Calculation of genome-wide z-scores
In order to establish a genome-wide z-score to detect
aberrant genomic content in plasma, we divided the
genome into equally-sized regions of 1 Mbp length and
calculated z-scores therein.
Under the condition that all ratios were drawn from
the same normal distribution, z-scores are distributed
proportionally to Student’s t-distribution with n-1
degrees of freedom. For controls, z-scores were calcu-
lated using cross-validation. In brief, z-score calculation
of one control is based on means and standard deviation
of the remaining controls. This prevents controls from
serving as their own controls.
The variance of these cross-validated z-scores of con-
trols is slightly higher than the variance of z-scores of
tumor patients. Thus ROC performance is underesti-
mated. This was confirmed in the simulation experiment
described below.
In order to summarize the information about high or
low z-score that was observed in many tumor patients
squared z-scores were summed up.
S =
∑
i from all Windows
z2i
Genome-wide z-scores were calculated from S-scores.
Other methods of aggregation of z-score information,
such as sums of absolute values or PA scores [38], per-
formed poorer and were therefore not considered. Per
window z-scores were clustered hierarchically by the
hclust function of R using Manhattan distance that
summed up the distance of each window.
In order to validate the diagnostic performance of the
genome-wide z-score in silico, artificial cases and con-
trols were simulated from mean and standard deviations
of ratios from 10 healthy controls according to a normal
distribution. Simulated tumor cases were obtained
through multiplication of the mean by the empirical
copy number ratio of 204 prostate cancer cases [9]. Seg-
mented DNA-copy-number data were obtained via the
cBio Cancer Genomics Portal [51].
To test the specificity of our approach at varying
tumor DNA content, we performed in-silico dilutions of
simulated tumor data. To this end we decreased the
tumor signal using the formula below, where l is the
ratio of tumor DNA to normal DNA:
(1 − λ) + λ · ratiosegment
We performed ROC analyses of 500 simulated con-
trols and 102 published prostate tumor data and their
respective dilutions using the pROC R-package [52].
The prostate tumor data were derived from a previously
published dataset [9] and the 102 cases were selected
based on their copy number profiles.
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Gene-Breakpoint Panel: target enrichment of cancer
genes, alignment and SNP-calling, SNP-calling results
We enriched 1.3 Mbp of seven plasma DNAs (four
CRPC cases, CRPC1-3 and CRPC5; three CSPC cases,
CSPC1-2 and CSPC4) including exonic sequences of 55
cancer genes and 38 introns of 18 genes, where fusion
breakpoints have been described using Sure Select Cus-
tom DNA Kit (Agilent, Santa Clara, CA, USA) following
the manufacturer’s recommendations. Since we had very
low amounts of input DNA we increased the number of
cycles in the enrichment PCR to 20. Six libraries were
pooled equimolarily and sequenced on an Illumina
MiSeq (Illumina, San Diego, CA, USA).
We generated a mean of 7.78 million reads (range, 3.62-
14.96 million), 150 bp paired-end reads on an Illumina
MiSeq (Illumina, San Diego, CA, USA). Sequences were
aligned using BWA [53] and duplicates were marked
using picard [54]. We subsequently performed realigning
around known indels and applied the Unified Genotyper
SNP-calling software provided by the GATK [55].
We further annotated resulting SNPs by employing
annovar [56] and reduced the SNP call set by removing
synonymous variants, variants in segmental duplications
and variants listed in the 1000 Genome Project [57] and
Exome sequencing (Project Exome Variant Server, NHLBI
Exome Sequencing Project (ESP), Seattle, WA) [58] with
allele frequency >0.01.
We set very stringent criteria to reduce false positives
according to previously published values [37]: a mutation
had to be absent from the constitutional DNA sequencing
and the sequencing depth for the particular nucleotide
position had to be >20-fold. Furthermore, all putative
mutations or breakpoint spanning regions were verified by
Sanger sequencing.
Split-read analysis
Since plasma DNA is fragmented the read pair method is
not suitable for identification of structural rearrange-
ments [59] and therefore we performed split-read analy-
sis of 150 bp reads. We used the first and the last 60 bp
of each read (leaving a gap of 30 bp) and mapped these
independently. We further analyzed discordantly mapped
split-reads by focusing on targeted regions and filtering
out split-reads mapping within repetitive regions and
alignments having a low mapping quality (<25). Reads
where discordantly mapped reads were found were
aligned to the human genome using BLAT [60] to further
specify putative breakpoints.
Data deposition
All sequencing raw data were deposited at the European
Genome-phenome Archive (EGA) [61], which is hosted by
the EBI, under accession numbers EGAS00001000451
(Plasma-Seq) and EGAS00001000453 (Gene-Breakpoint
Panel).
Results
Implementation of our approach
Previously, we demonstrated that tumor-specific, somatic
chromosomal alterations can be detected from plasma of
patients with cancer using array-CGH [33]. In order to
extend our method to a next-generation sequencing-
based approach, that is, plasma-Seq, on a benchtop Illu-
mina MiSeq instrument, we first analyzed plasma DNA
from 10 men (M1 to M10) and nine women (F1 to F9)
without malignant disease. On average we obtained 3.3
million reads per sample (range, 1.9-5.8 million; see
Additional file 1, Table S2) and applied a number of fil-
tering steps to remove sources of variation and to remove
known GC bias effects [62-64] (for details see Material
and Methods).
We performed sequential analyses of 1-Mbp windows
(n=2,909 for men; n=2,895 for women) throughout the
genome and calculated for each 1-Mbp window the
z-score by cross-validating each window against the
other control samples from the same sex (details in
Material and Methods). We defined a significant
change in the regional representation of plasma DNA
as >3 SDs from the mean representation of the other
healthy controls for the corresponding 1-Mbp window.
A mean of 98.5% of the sequenced 1-Mbp windows
from the 19 normal plasma samples showed normal
representations in plasma (Figure 1a). The variation
among the normalized proportions of each 1-Mbp win-
dow in the plasma from normal individuals was very
low (average, 47 windows had a z-score £-3 or ≥3;
range of SD, ±52%) (Figure 1a).
In addition, we calculated ‘segmental z-scores’ where
the z-scores are not calculated for 1-Mbp windows but
for chromosomal segments with identical copy number.
In order to determine such segments we employed an
algorithm for the assignment of segments with identical
log2 ratios [39,46] (Material and Methods) and calculated
a z-score for each of these segments (hence, ‘segmental
z-scores’). As sequencing analyses of chromosome con-
tent in the maternal circulation are now frequently being
used for detection of fetal aneuploidy [34,36] and as our
mean sequencing depth is lower compared to previous
studies, we wanted to test whether our approach would
be feasible for this application. To this end we obtained
two plasma samples each of pregnancies with euploid
and trisomy 21 fetuses and one each of pregnancies with
trisomies of chromosomes 13 and 18, respectively. In the
trisomy cases the respective chromosomes were identi-
fied as segments with elevated log2 ratios and accordingly
also increased z-scores (Additional file 2).
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Sensitivity and specificity of our approach
We wanted to gain insight into the sensitivity of our
approach to detect tumor-derived sequences in a patient’s
plasma. To this end we calculated a genome-wide z-score
for each sample (Material and Methods). The main pur-
pose of the genome-wide z-score is to distinguish between
aneuploid and euploid plasma samples. The genome-wide
z-score from the plasma of male individuals ranged from
-1.10 to 2.78 and for female individuals from -0.48 to 2.64.
We performed receiver operating characteristic (ROC)
analyses of simulated next-generation sequencing data
from 102 published prostate cancer data and 500 simu-
lated controls based on the data from our healthy indivi-
duals. Using the equivalent of one-quarter MiSeq run,
these analyses suggested that using the genome-wide
z-score tumor DNA concentrations at levels ≥10% could
be detected in the circulation of patients with prostate
cancers with a sensitivity of >80% and specificity of >80%
(Figure 1c).
To test these estimates with actual data we fragmented
DNA from the colorectal cancer cell line HT29 to sizes
of approximately 150-250 bp to reflect the degree of frag-
mented DNA in plasma and performed serial dilution
experiments with the fragmented DNA (that is, 50%,
20%, 15%, 10%, 5%, 1%, and 0%). We established the
copy-number status of this cell line with undiluted, that
is, 100%, DNA using both array-CGH and our next-
generation sequencing approach (Additional file 3) and
confirmed previously reported copy number changes
[65,66]. Calculating the genome-wide z-score for each
dilution we noted its expected decrease with increasing
dilution. Whereas the genome-wide z- score was 429.74
for undiluted HT29 DNA, it decreased to 7.75 for 1%
(Additional file 1, Table S2). Furthermore, when we per-
formed hierarchical cluster analysis the female controls
were separated from the various HT29 dilutions, further
confirming that our approach may indicate aneuploidy in
the presence of 1% circulating tumor DNA (Figure 1d).
Plasma analysis from patients with cancer
Our analysis of plasma samples from patients with can-
cer is two-fold (Figure 2): (a) we used plasma-Seq to
calculate the genome-wide z-score as a general measure
for aneuploidy and the segmental z-scores to establish a
genome-wide copy number profile. The calculation of
the segments with identical log2 ratios takes only 1 h
and also provides a first assessment of potential copy
number changes. Calculation of the z-scores for all seg-
ments and thus definite determination of over- and
under-represented regions requires about 24 h. (b) In
addition, we sequenced with high coverage (approxi-
mately 50x) 55 genes frequently mutated in cancer
according to the COSMIC [67] and Cancer Gene Cen-
sus [68] databases (Additional file 1, Table S3), and 38
introns often involved in structural somatic rearrange-
ments, including recurrent gene fusions involving mem-
bers of the E twenty-six (ETS) family of transcription
factors to test for TMPRSS2-ERG-positive prostate
Figure 1 Implementation of our approach using plasma DNA samples from individuals without cancer and simulations. (a) Z-scores
calculated for sequential 1-Mbp windows for 10 male (upper panel) and 9 female (lower panel) individuals without malignant disease. (b)
Detection of tumor DNA in plasma from patients with prostate cancer using simulated copy-number analyses. ROC analyses of simulated
mixtures of prostate cancer DNA with normal plasma DNA using the genome-wide z-score. Detection of 10% circulating tumor DNA could be
achieved with a sensitivity of >80% and specificity of >80%. (c) Hierarchical cluster analysis (Manhattan distances of chromosomal z-scores) with
normal female controls and the HT29 serial dilution series. One percent of tumor DNA still had an increased genome-wide z-score and did not
cluster together with the controls (for details see text).
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cancers (herein referred to as GB-panel (Gene-Break-
point panel)). In a further step identified mutations were
verified by Sanger sequencing from both plasma DNA
and constitutional DNA (obtained from a buccal swab)
to distinguish between somatic and germline mutations.
If needed, somatic mutations can then be used to esti-
mate by deep sequencing the fraction of mutated tumor
DNA in the plasma.
Figure 2 Outline of our whole-genome plasma analysis strategy. After blood draw, plasma preparation, and DNA-isolation we start our
analysis, which is two-fold: first (left side of the panel), an Illumina shotgun library is prepared (time required, approximately 24 h). Single-read
whole genome plasma sequencing is performed with a shallow sequencing depth of approximately 0.1x (approximately 12 h). After alignment
we calculate several z-scores: a genome-wide z-score, segments with identical log2-ratios required to establish corresponding segmental z-
scores, and gene-specific z-scores, for example, for the AR-gene. Each of these z-scores calculations takes approximately 2 h so that these
analyses are completed within 48 h and the material costs are only approximately €300. Second (right side of the panel), we prepare a library
using the SureSelect Kit (Agilent) and perform sequence enrichment with our GB-panel (approximately 48-72 h), consisting of 55 high-interest
genes and 38 introns with frequent fusion breakpoints. The GB-panel is sequenced by paired-end sequencing with an approximately 50x
coverage (around 26 h). The evaluation of the sequencing results may take several hours, the confirmation by Sanger sequencing several days.
Hence, complete analysis of the entire GB-panel analysis will normally require around 7 days.
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Plasma-Seq and GB-panel of patients with prostate cancer
We then obtained 13 plasma samples from nine patients
with metastatic prostate cancer (five with castration-
resistant disease, CRPC1 to CRPC5, and four with cas-
tration-sensitive disease, CSPC1 to CSPC4. Furthermore,
from each of patients CRPC1 and CSPC1 we obtained
three samples at different time points (Clinical data in
Additional file 1, Table S1). Applying plasma-Seq, we
obtained on average 3.2 million reads (range, 1.1
(CSPC4) to 5.2 (CRPC5) million reads) for the plasma
samples from patients with prostate cancer per sample
(see Additional file 1, Table S2).
To assess whether plasma-Seq allows discrimination
between plasma samples from healthy men and men
with prostate cancer we first calculated the genome-
wide z-score. In contrast to the male controls (Figure
1a), the 1-Mbp window z-scores showed a substantial
variability (Figure 3a) and only a mean of 79.3% of the
sequenced 1-Mbp windows from the 13 plasma samples
showed normal representations in plasma in contrast to
99.0% of the cross-validated z-scores in the sample of
controls (P=0.00007, Wilcoxon test on sample percen-
tages). Accordingly, the genome-wide z-score was ele-
vated for all prostate cancer patients and ranged from
125.14 (CRPC4) to 1155.77 (CSPC2) (see Additional file
1, Table S2). Furthermore, when we performed hierarch-
ical clustering the normal samples were separated from
the tumor samples (Figure 3b), suggesting that we can
indeed distinguish plasma samples from individuals
without malignant disease from those with prostate
cancer.
Applying the GB-panel, we achieved on average a
coverage of ≥50x for 71.8% of target sequence (range,
67.3% (CSPC4) to 77.6% (CSPC2)) (see Additional file 1,
Figure 3 Copy number analyses of plasma samples from men with prostate cancer. (a) Z-scores calculated for 1-Mbp windows from the
13 plasma samples of patients with prostate cancer showed a high variability (compare with same calculations from men without malignant
disease in Figure 1a, upper panel). (b) Hierarchical clustering (Manhattan distances of chromosomal z-scores) separates samples from men
without cancer and with prostate cancer. (c) Copy number analyses, based on segmental z-scores, of an unmatched normal male plasma sample
and five plasma samples from patients with prostate cancer (CRPC2, CRPC3, CRPC5, CSPC2, and CSPC4). The Y-axis indicates log2-ratios.
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Table S4). Using very stringent conditions (see Material
& Methods) the GB-panel allowed us to identify 12
mutations in all seven patients for which the analyses
were performed (that is, CRPC1-3, CRPC5, CSPC1-2,
and CSPC4). Sanger sequencing confirmed the presence
of five of these mutations in both plasma and the
respective constitutional DNA, whereas seven mutations
were only confirmed in plasma but not in the constitu-
tional DNA. The latter mutations, which were observed
in five patients (that is, CRPC2-3, CRPC5, CSPC2,
CSPC4), are likely somatic mutations and occurred in
genes previously implicated in prostate cancer tumori-
genesis, such as TP53, BRCA1, BRCA2, and MLL3 (see
Additional file 1, Table S4). We used these somatic
mutations for ultra-deep sequencing with an average
coverage of 362,016 (range, 307,592 to 485,467) to esti-
mate the tumor fraction. Using these estimates the
tumor fraction was lowest in CSPC4 with 30.75% and
highest in CRPC5 with 54.49%.
Plasma-Seq from these patients exhibited a wide range
of copy number aberrations indicative of malignant ori-
gin, including those that have been previously reported
in prostate tumors. For example, the three CRPC
patients (that is, CRPC2-3, CRPC5) had high-level gains
in a region on chromosome × including the AR locus.
Over-representation of 8q regions was observed in all
five patients and loss of 8p regions in three patients
(CRPC5, CSPC2, and CSPC4) (Figure 3c).
As control we performed array-CGH analyses of all
plasma cases as described [33] in parallel (see Additional
file 4). These array-CGH profiles had a great concor-
dance with those obtained with plasma-Seq.
TMPRSS2-ERG fusion mapping
The fusion through deletion TMPRSS2-ERG rearrange-
ment results in a well-defined 3-Mbp interstitial deletion
on chromosome 21 [69,70] and occurs in approximately
50% of prostate cancer cases [71]. We tested whether our
approach would allow distinguishing TMPRSS2-ERG-
positive from TMPRSS2-ERG-negative prostate cancers.
Plasma-Seq identified a 3-Mbp deletion at the TMPRSS2-
ERG location on chromosome 21 in five patients (CRPC1,
CRPC3, CRPC5, CSPC1, and CSPC4) (Figure 4). To further
confirm the presence of the deletions we analyzed the
sequences obtained with the GB-panel with the split-read
method (see Material and Methods). We identified several
fusion spanning reads in each of the aforementioned
patients (see Additional file 1, Table S4), which enabled us
to map the breakpoints with bp resolution (Figure 4). Most
of our deletions originate from exon 1 of TMPRSS2 and are
fused to exon 3 of ERG consistent with previous reports
[71]. We then further confirmed all TMPRSS2-ERG fusions
with Sanger sequencing (data not shown).
Analyses of serial plasma samples
We had the opportunity to perform serial plasma ana-
lyses from two patients: CRPC1 and CSPC1. CRPC1 had
his primary tumor completely resected in 1999, (13 years
before we performed our plasma analyses). Since the pri-
mary tumor appeared to be very heterogeneous (see
Additional file 5) pathologist-guided dissection was care-
fully performed from six different regions (designated as
T2-T7). We performed our whole-genome sequencing
analysis for each region separately and found different
copy-number changes in each sector. Common changes
included partial gain of 16p (observed in T2, T4, T5, T6,
and T7) and partial losses of 10q (T2, T6, T5, and T7),
13q (T2, T6, and T7), and 16q (T2, T5, T6, and T7)
(Figure 5). These various findings in different tumor sec-
tors are consistent with a multifocal disease, which is fre-
quently encountered in prostate cancer [16].
Plasma samples were taken at three different time points
over a 9-month period (we refer to them in addition to
CRPC1 as CRPC1_2 and CRPC1_3). At the time of our
plasma collections the patient was castration resistant
and had stable disease under ongoing ADT and che-
motherapy. Plasma-Seq identified again multiple pros-
tate cancer-associated chromosomal alterations, such as
8p loss, gain of 8q regions, the 3-Mbp TMPRSS2-ERG
deletion on chromosome 21, and AR amplification
(Figures 4 and 5). Thus, plasma-Seq identified multiple
rearrangements, that is, the TMPRSS2-ERG deletion on
chromosome 21, which had not been present in the
primary tumor. Furthermore, plasma-Seq yielded
remarkably similar results in our three analyses over the
9-month period (Figure 5), which is in agreement with
the clinically stable disease and suggests the presence of
one dominant clone releasing DNA into the circulation.
This is consistent with the proposed monoclonal origin
of metastatic prostate cancer [8]. Hierarchical clustering
confirmed the concordance between the three plasma-
Seq copy number profiles and the tremendous differ-
ences to the various sectors of the primary tumor
(Figure 5).
We collected the first plasma sample from CSPC1
about 12 months after initial diagnosis and two other
samples over a 6-month period (CSPC1, CSPC1_2, and
CSPC1_3). Only a biopsy had been taken from the pri-
mary tumor to confirm diagnosis. The patient was clini-
cally responding to castration therapy. We observed
again a number of copy number changes, many of those
characteristic of prostate cancer (Figure 6), such as the
TMPRSS2-ERG deletion (Figure 4). There was no AR
amplification as expected for a CSPC case.
The high similarity of copy number changes at various
time points is another confirmation of the high reliabil-
ity and robustness of our approach.
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Evaluation of copy number changes of prostate cancer
genes
The evaluation of 1-Mbp or segmental z-scores each
involves relatively large regions. We wanted to test
whether z-scores can also be calculated for much smal-
ler regions, that is specific genes, and calculated gene-
specific z-scores (see Material & Methods).
For example, in prostate cancer, one of the most inter-
esting regions is the AR-locus on chromosome Xq12,
which is amplified in approximately 33% of patients with
CRPC [72]. As expected, none of the male healthy con-
trols had an amplification of AR, whereas AR amplifica-
tion was present in four of the five CRPC cases. In order
to validate the plasma-Seq gene-specific copy number
estimates with another approach we selected a subset of
samples (CRPC1, CRPC2, CRPC5, CSPC1, CSPC1_2, and
CSPC2) for validation of the AR copy-number status with
qPCR. In fact, we observed a very close correlation
between the plasma-Seq and the qPCR values (see Addi-
tional file 6). Interestingly, CRPC1 had only a duplication
of the AR region and the AR copy number did not change
over our observation period of 9 months, which was con-
sistent with the clinically stable disease. One of the CSPC
cases, CSPC4, had a slightly increased AR ratio (ratio,
1.46; z-score, 4.60). Whether such a value may indicate
the beginning of ADT resistance remains presently
unclear, as sufficient follow-up data were not available.
We also tested our approach for some other genes,
which have frequently been implicated in prostate cancer.
For example, evidence for cooperation between AR and
NCOA2 amplifications on 8q13.3 in early prostate cancer
was reported [73]. However, alternatively it was sug-
gested that tumors first acquire NCOA2 amplification
along with broad amplifications on chromosome 8q [6].
Figure 4 Identification of the TMPRSS2-ERG associated 3-Mb deletion on chromosome 21 and mapping of the breakpoints. Exemplary
log2 ratio plots of chromosome 21 from plasma DNA of several patients (regions with log2 ratios >0.2 are shown in red and those with log2
ratios <-0.2 in blue). A deletion with size of 3 Mbp located at the TMPRSS2-ERG region was visible in patients CRPC1, CRPC5, CSPC4, and CSPC1.
For comparison we also included chromosome 21 plots from CSPC2 and CRPC2 without this deletion. Mapping of the exact breakpoints was
based on fusion transcripts identified with our GB-panel. In CRPC1, CRPC5, and CSPC4 the breakpoints were in exon 1 of the TMPRSS2 gene and
exon 3 of the ERG gene, respectively (center panel). In CSPC1 the proximal breakpoint was approximately 24 Kb upstream of the ERG gene.
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Figure 5 Analyses of tumor and serial plasma samples from patient CRPC1. DNA was extracted from six different regions (designated as
T2-T7) from the primary tumor and separately analyzed by our whole-genome sequencing approach (corresponding histology images are in
Additional file 5). The first plasma sample (CRPC1) was obtained 13 years after resection of the primary tumor, the interval between the first and
second (CRPC1_2) sample was 7 months and between the second and third (CRPC1_3) 2 months. The patient had stable disease under AD and
chemotherapy. Hierarchical clustering (Manhattan distances of chromosomal z-scores) of the plasma samples and the sectors of the primary
tumor is shown on the left side, the samples are shown in the corresponding order.
Figure 6 Analyses of serial plasma samples from patient CSPC1. The first plasma sample (CSPC1) was collected 12 months after initial
diagnosis, only a biopsy had been taken from the primary tumor to confirm diagnosis. The interval between the first and second (CSPC1_2)
sample was 5 months and 1 month between the second and third (CSPC1_3). The patient was clinically responding to castration therapy.
Heitzer et al. Genome Medicine 2013, 5:30
http://genomemedicine.com/content/5/4/30
Page 11 of 16
Our gene-specific z-score identified NCOA2 gene ampli-
fications in five patients (CRPC1, CRPC5, CSPC1-3),
thus, two CRPC and three CSPC cases, which may sup-
port the notion that NCOA2 amplifications may occur
prior to AR amplification [6].
Loss of PTEN on 10q23.31 occurs in approximately
40% of prostate cancers [9,74]. We observed PTEN loss
in five patients (CRPC3-5, CSPC1, and CSPC3); that is,
in three CRPC and two CSPC cases. The AKT-inactivat-
ing phosphatase PHLPP1 on 18q21.33 has recently been
identified as a prostate tumor suppressor [75]. We found
that this gene was lost in four patients (CRPC1, CRPC3,
CSPC1-2); that is, in two CRPC and two CSPC cases.
Furthermore, it has recently been reported that the
TMPRSS2-ERG fusion is associated with a deletion at
chromosome 3p14 that includes the FOXP1 gene [9]. In
fact, we observed loss of this region in five of our patients
(CRPC1-2, CRPC4, CSPC1, CSPC4) and four of these
patients (CRPC1-2, CSPC1, CSPC4) did indeed have the
TMPRSS2-ERG fusion, confirming the association
between these two loci.
In summary, our results suggest that gene-specific
information can be derived from plasma-Seq, which
may facilitate the evaluation of pathways potentially
comprised in prostate cancer.
Discussion
This study represents the first whole-genome sequencing
analysis from plasma DNA of patients with prostate can-
cer. Usually the identification of tumor genotypes that
inform selection of targeted therapies is performed on
the initial diagnostic specimen. However, these may not
be readily available or in case of fine needle aspirates not
sufficient for molecular analyses, as was the case for our
patients who presented with metastatic disease. The only
exception in our cohort was CRPC1, who had recurrent
disease many years after initial operative treatment. We
could demonstrate that the initial primary tumor speci-
men represented multifocal disease and none of the ana-
lyzed sectors was representative of the metastatic clone,
which arose 13 years later. Thus, molecular analysis of
plasma may provide a non-invasive approach for tumor
cell genotyping, which can easily be repeated during the
course of therapy.
Multiple lines of evidence support the copy number
changes observed. First, the observation of known pros-
tate cancer alterations in our dataset indicates successful
performance of our assay. Second, our previously pub-
lished array-based plasma method [33] was applied in
parallel to confirm the copy number aberrations observed
with plasma-Seq. Third, we identified the well character-
ized 3-Mbp interstitial 21q22.2-3 deletion spanning ERG
and TMPRSS2 on chromosome 21 [69,70] and confirmed
its presence with our GB-panel and Sanger sequencing.
Fourth, for two of our patients we were able to repeat
our analysis at different time points. These repeated ana-
lyses revealed a high degree of similarity among samples
from the same patient. The shared copy number aberra-
tions were indicative of common lineage, which is consis-
tent with the view that metastases in this disease are of
monoclonal origin [8]. Finally, implementation of our
approach with 19 samples from individuals without can-
cer and five plasma samples from pregnant females with
aneuploidy fetuses further confirmed the reliability and
robustness of our approach.
Tests for sensitivity and specificity of our approach
suggested that tumor DNA concentrations at levels ≥10%
can be detected with a sensitivity of >80% and specificity
of 80%. Furthermore, our simulations and HT29 dilution
experiments suggested that the genome-wide z-score
detects aneuploidy even at tumor DNA concentrations of
only 1%. In general, the resolution of non-invasive tumor
genome-wide scans from plasma is limited by the depth
of the sequencing and the percentage of tumor fragments
in the plasma. Therefore, previously published similar
studies [37,38] employed high-throughput sequencing
platforms tailored chiefly toward large-scale applications.
As a consequence, footprints, workflows, reagent costs,
and run times are poorly matched to the needs of small
laboratories and furthermore, the cost of the sequencing
necessary for detection of rearrangements at this level is
prohibitive for routine clinical implementation [38]. In
contrast, advantages of a benchtop high-throughput
sequencing instrument include the speed of analyses and
the reduced costs. A MiSeq run produces a throughput
of 1.6 Gbp with a read length of 150 bp [40]. As whole-
genome sequencing with a 0.1x coverage was reported to
yield robust and reliable copy-number measurements
from single cells [39], we tested such a sequencing
approach for our plasma analyses. Accordingly, we found
that the characteristics of the MiSeq are sufficient for our
plasma-Seq purposes. Especially attractive features of this
strategy include the speed (library prep, approximately 24
h; sequencing of 150 bp single reads, approximately 12 h;
identification of segments with identical log2 ratios,
approximately 2 h; calculation of z-scores, 30 min) and
the costs (approximately €300) with which the aneu-
ploidy scoring by plasma-Seq can be performed. In con-
trast, completion of the GB-panel analysis, done at 50x
coverage, will normally require at least 7 days (library
prep, approximately 24 h; targeted enrichment, approxi-
mately 48-72 h; sequencing 150 bp paired end, approxi-
mately 26 h; evaluation and SNP calling, several hours)
not including verifications of mutations by Sanger
sequencing or estimation of the fractional load of tumor
fragments by deep sequencing.
A disadvantage of low coverage whole-genome sequen-
cing is that structural inter- and intrachromosomal
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rearrangements cannot be identified with high confi-
dence. This is because plasma DNA fragments, whose
paired-end reads map to different chromosomes or to
the same chromosome but at large distances (several kb)
apart, will likely not be detected in multiple reads.
Another disadvantage is the reduced resolution for iden-
tification of mutations. However, several large scale
whole-exome or whole-genome sequencing studies con-
sistently reported low overall mutation rates even in
heavily treated CRPCs ranging from 0.9 to 2.00 muta-
tions per mega base [9,11-14]. These studies confirmed
that the most commonly mutated gene was AR, however
no single gene other than AR had frequent mutations
and even common, broadly mutated oncogenes such as
PIK3CA, KRAS, and BRAF are not commonly mutated in
prostate cancer [9]. We addressed both issues, structural
rearrangements and mutations, with a focused sequen-
cing approach with higher coverage. Focused sequencing,
such as our GB-panel, with tailored design and analytical
prioritization strategies may represent an attractive alter-
native to large-scale whole-genome sequencing in terms
of speed and costs. Such a focused approach is flexible
and can easily be adapted if new, important genes or
regions evolve from large-scale sequencing projects.
Another potential short-coming is that we do not know
whether the changes observed in the plasma are related to
the primary tumor or to any of the metastatic sites. In fact,
it is currently unknown whether all tumor cells contribute
to the plasma DNA equally and which factors influence
the release of tumor DNA into the circulation. Further
studies are needed to determine whether changes observed
by plasma-Seq represent an average of the DNA altera-
tions from all malignant sites or whether they show char-
acteristic changes of the dominant tumor cell clone at the
time of the blood collection.
At present we do not know how our plasma DNA signa-
tures perform compared with other emerging candidate
markers, for example, CTC analysis [24]. However, our
approach circumvents an inherent limitation of all pub-
lished CTC-based studies, that is, it is not focused on
EpCAM-positive CTCs. Furthermore, plasma isolation
does not necessitate special equipment as usually required
for CTC isolation [21-23]. As we already have plasma-Seq
data from patients with colon and breast cancer our
method may also be applicable to other tumor types.
Whether these blood copy-number signatures will be
true game changers for the management of prostate can-
cer has to be further evaluated. Drug development for
castration-resistant prostate cancer is an area of intensive
research and several new agents are currently being
tested in phase 3 clinical trials. Interrogation of the geno-
mic signature may reveal whether those targeted thera-
pies are effectively hitting their target in vivo, thus
providing information that may be useful in guiding ther-
apeutic decisions.
Conclusions
Our strategy may contribute to a better definition of the
evolution towards a castration-resistant disease and
could potentially aid in identifying patients more or less
likely respond to AR-targeted therapies. The simplicity
and the costs of our test are attractive and might ease
the clinical translation. However, the extent to which
these signatures contribute independent prognostic or
predictive value beyond clinicopathological variables
must be explored in more depth.
Additional material
Additional file 1: Supplementary tables 1-4.
Additional file 2: Plasma DNA analyses from pregnant women.
Plasma DNA analyses from maternal blood with pregnancies with a
trisomy 21 fetus (first panel), a trisomy 13 fetus (second panel), a trisomy
18 fetus (third panel), and an euploid fetus (fourth panel) (X-axis:
Chromosome; Y-axis: z-score).
Additional file 3: Copy-number status of the HT29 cell line. The
upper panel illustrates the array-CGH profile, the lower panel the profile
obtained with our next-generation sequencing approach. Both panels
illustrate the copy number profile with undiluted, that is, 100%, DNA. In
the array-CGH profile the multicolor bar codes at the top or bottom of
the ratio profiles illustrate the results obtained during the iterative
calculations with various window sizes, the single green and red bars
summarize the regions which were gained or lost based on all
calculations (for details see [44]). Black parts in the profile represent
balanced regions, lost regions appear in red, and gained regions in
green.
Additional file 4: Array-CGH evaluations as control for our plasma-
Seq approach: Array-CGH profiles of plasma samples CRPC2,
CRPC3, CRPC5, CSPC2, and CSPC4. For all array-CGH profiles the
multicolor bar codes at the top or bottom of the ratio profiles illustrate
the results obtained during the iterative calculations with various
window sizes, the single green and red bars summarize the regions
which were gained or lost based on all calculations (for details see [44]).
Black parts in the profile represent balanced regions, lost regions appear
in red, and gained regions in green. Previously we had already
demonstrated the use of array-CGH analyses for the analysis of plasma
DNA [33]. The array-CGH profiles show a great concordance with those
obtained with plasma-Seq.
Additional file 5: Histology samples from the primary tumor of patient
CRPC1. The six different samples are arranged according to the
hierarchical clustering (Manhattan distances of chromosomal z-scores)
from Figure 5, the corresponding part of the tree is shown to the left.
From each sector the most common (left) and second most common
(right) patterns are shown. Relating the hierarchical clustering of the
chromosomal alterations in the various sectors of the primary tumor to
morphological features, no clear picture emerges. Regarding the growth
pattern, T2 and T3 seem closely related as are T4 and T5, which is not
reflected in the clustering analysis of the chromosomal alterations. Based
on nuclear staining features, T7 seems similar to T2 and T3. T6 also
shares features of T2 and T3. Taking into account the changes detected
in circulating DNA, the most likely explanation is a complex multifocal
disease resulting in a complex morphological as well as genetic pattern.
Additional file 6: Validation of the AR copy number status with qPCR
for plasma samples CRPC1, CRPC2, CRPC5, CSPC1, CSPC1_2, and CSPC2
showing a very close correlation between the plasma-Seq and the qPCR
values.
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